Korea Arlico Pharm stock price

알리코제약KRX:260660 · KOSDAQ · Healthcare · sector #23
₩2,425+2.54%
2026-10-08 close
Loading chart…

Korea Arlico Pharm's chart data is dated 2026-10-08. Recorded technical signals: MACD bullish cross. There are 0 published signal records.

Korea Arlico Pharm last closed at ₩2,425 (+2.54%) on 2026-10-08. Signals today: MACD bullish cross. Listed on KOSDAQ. Trailing 12 months PER is -12.3×. Its overall grade ranks 268 of 308 stocks in Healthcare.

About this company

Korea Arlico Pharm last closed at ₩2,425 (+2.54%) on 2026-10-08. Signals today: MACD bullish cross. Listed on KOSDAQ.

Details →

Reported results

Details →

Position in sector

Healthcare · Overall D · 268/308

Valuation grade A+

Details →

Dividends

2025 dividend per share · ₩75 · Yield 3.31%

Details →

Recent filings

DART · received recent list, not a complete filing history. Factual information, not investment advice.

Details →

Related stocks

  • 한미약품Competitor

    전문의약품·개량신약 중심 국내 제약 경쟁사

  • 대웅제약Competitor

    국내 처방의약품 시장에서 경쟁하는 주요 제약사

  • 종근당Competitor

    의약품 원료·완제 및 병원/처방 시장 경쟁사

Details →
About Korea Arlico Pharm
What technical signals does Korea Arlico Pharm (260660) have?
Korea Arlico Pharm current technical signals: MACD bullish cross.
Is Korea Arlico Pharm a cup-and-handle pattern?
No. Korea Arlico Pharm has no valid Cup signal right now.
What published figures are available for Korea Arlico Pharm?
Market cap: KRW 37.17B. Trailing 12 months PER: -12.3×. Latest quarter PBR: 0.46×. Dividend yield: 3.31%.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Major stocks in the same sector

2026-10-09 dataset

Turn what you saw on this name into a strategy

Ask Q about Korea Arlico Pharm, or open the plan table on the main site.

From the names you found to a trading rule

Tell Q about the stocks you found to place orders with your conditions.

See plans ↗

Korea Arlico Pharm notifications

Quantus Signal · live data · not investment advice · Privacy Policy